Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Stock Information for Markforged Holding Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Markforged Holding Corporation

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
Vaxart Announces Adjournment of Annual Meeting of Stockholders
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders
Vaxart Answers Additional Frequently Asked Questions from Retail Investors
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
Vaxart Announces Adjournment of Annual Meeting of Stockholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.